PPG, PPG Foundation invested $18.4 million in communities worldwide in 2024
PPG (NYSE:PPG) and the PPG Foundation today announced that they invested $18.4 million worldwide in 2024, an increase of $900,000 over 2023. The 2024 funding supported more than 400 community partners and programs that focus on advancing education and delivering community sustainability while encouraging PPG employee volunteerism.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219834296/en/
PPG and the PPG Foundation invested $18.4 million worldwide in 2024 to programs that focus on advancing education and delivering community sustainability while encouraging PPG employee volunteerism. (Photo: Business Wire)
“Around the world, PPG’s 2024 community engagement investments aimed to inspire students and aspiring STEM leaders, beautify neighborhoods and give our employees meaningful ways to give back,” said Malesia Dunn, executive director, PPG Foundation and corporate global social responsibility. “We’re focused on creating brighter communities, inspiring the future workforce and applying our employees’ talents in ways that create tangible impacts.”
Highlights of the 2024 community engagement commitments include:
- $11.5 million to build the next generation of STEM leaders.
- PPG expanded its partnership with the National Museum of Science and Technology Leonardo da Vinci in Milan to open Playlab, a unique educational space for young children.
- PPG entered a two-year partnership with the Foundation for Environmental Education (FEE) to support the creation of materials including “Eco-Schools” handbooks, instructional videos, online courses and training materials for teachers.
- In Pittsburgh and Detroit, the PPG Foundation partnered with nonprofit Code/Art to expand access to computer science programs for girls that blend art and technology.
- In Sumaré, Brazil, PPG launched the third edition of “Girls in Tech,” an initiative with nonprofit Casa Hacker to empower young women to pursue careers in technology.
- Progress toward our commitments.
- $1.2 million invested toward the $5 million commitment by 2030 to environmental sustainability education, supporting organizations such as the National Energy Education Development (NEED) in the U.S., Junior Uni Wuppertal’s sustainability courses in Germany, and the Attitude for the Planet program with Junior Achievement in Brazil.
- PPG completed its $2 million commitment by 2025 to future skilled worker training through organizations including the Bidwell Training Center’s Chemical Laboratory Technician program in the U.S.; technical education program 42KL in Malaysia; donations of PPG LINQ™ innovative tools to vocational schools in Europe; and WorldSkills Lyon 2024, the world’s largest vocational skills competition.
- $6.4 million to community sustainability and disaster relief.
- PPG and the PPG Foundation contributed to organizations supporting emergency relief, including the Red Cross, following natural disasters and extreme weather in the southeastern U.S. and across Europe.
- 58 COLORFUL COMMUNITIES® projects completed in 2024 in 27 countries.
- PPG’s Colorful Communities program has now completed nearly 600 projects since 2015. More than 30,300 PPG employee and community volunteers have positively impacted over 10.2 million people in more than 50 countries.
- Throughout June, July and August 2024, the Colorful Communities program completed its third New Paint for a New Start initiative, transforming 90 schools into engaging environments for nearly 53,000 students and teachers from 2022 to 2024.
Learn more about PPG and the PPG Foundation’s investments in 2024.
PPG’s global community engagement efforts and the PPG Foundation aim to bring color and brightness to PPG communities around the world. We invested $18.4 million in 2024, supporting hundreds of organizations across more than 30 countries. By investing in educational opportunities, we help grow tomorrow’s STEM innovators and skilled workforce in fields related to coatings and manufacturing. Plus, we empower PPG employees to multiply their impact for causes that are important to them by supporting their volunteer efforts and charitable giving. Learn more here.
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for more than 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $15.8 billion in 2024. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
PPG LINQ is a trademark and Colorful Communities, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Community Affairs
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219834296/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom